Objective: Studies suggest that people with major depressive disorder (MDD) often receive treatment that is not concordant with practice guidelines. To evaluate this, we (1) developed a guideline concordance algorithm for MDD pharmacotherapy (GCA-8), (2) scored it using clinical data, and (3) compared its explanation of patient-reported symptom severity to a traditional concordance measure.
Methods: This study evaluated 1,403 adults (67% female, 85% non-Hispanic/Latino White, mean age 43 years) with non-psychotic MDD (per ICD-10 codes), from the Penn State Psychiatry Clinical Assessment and Rating Evaluation System (PCARES) registry (visits from February 1, 2015, to April 13, 2021). We (1) scored 1-year concordance using the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines and deviation from 8 pharmacotherapy-related criteria and (2) examined associations between concordance and Patient Health Questionnaire depression module (PHQ-9) scores.
Results: The mean GCA-8 score was 6.37 (standard deviation [SD] = 1.30; 8.00 = perfect concordance). Among those who switched drugs (n = 671), 81% (n = 542) did not have their dose increased to the recommended maximum before switching. In our adjusted analyses, we found that a 1 SD increase in the GCA-8 was associated with a 0.78 improvement in the mean PHQ-9 score (P < .001). The comparison concordance measure was not associated with the mean PHQ-9 score (β = −0.20; P = .20; R2 = 0.53), and adding the GCA-8 score significantly improved the model (R2 = 0.54; Vuong test P = .008).
Conclusions: By measuring naturalistic MDD pharmacotherapy guideline concordance with the GCA-8, we revealed potential treatment gaps and an inverse association between guideline concordance and MDD symptom severity.
J Clin Psychiatry 2024;85(1):23m14916
Author affiliations are listed at the end of this article.
Major depressive disorder is a serious mental illness. Doctors use guidelines to select the best treatment options for depression. This study created a new score to measure guideline adherence. Compared to older methods, the new score has a stronger connection to symptoms. These results help identify ways to improve the guidelines and patient care.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. IHME, University of Washington. Published 2020. Accessed March 26, 2023. https://vizhub.healthdata.org/gbd-compare
Hammer-Helmich L, Haro JM, Jönsson B, et al. Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatr Dis Treat. 2018;14:239–249. PubMedCrossRef
Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–665. PubMedCrossRef
Severe J, Greden JF, Reddy P. Consequences of recurrence of major depressive disorder: is stopping effective antidepressant medications ever safe? Focus Am Psychiatr Publ. 2020;18(2):120–128. PubMedCrossRef
Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. PubMedCrossRef
Saragoussi D, Touya M, Haro JM, et al. Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatr Dis Treat. 2017;13:2151–2165. PubMedCrossRef
Carrasco JL, Kornstein SG, McIntyre RS, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016;31(3):134–146. PubMedCrossRef
Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663–1672. PubMedCrossRef
DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677–688. PubMedCrossRef
Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. PubMedCrossRef
Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97–106. PubMedCrossRef
Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66. PubMedCrossRef
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMedCrossRef
Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161–175. PubMedCrossRef
Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189–198. PubMedCrossRef
Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004;56(1):46–53. PubMedCrossRef
Hengartner MP. How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychopharmacol. 2020;10:2045125320921694. PubMedCrossRef
Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826. PubMedCrossRef
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200. PubMedCrossRef
Lundberg J, Cars T, Lööv SÅ, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiatry. 2023;80(2):167–175. PubMedCrossRef
Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry. 2016;15(3):228–235. PubMedCrossRef
Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry. 2010;167(12):1445–1455. PubMedCrossRef
Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001;286(23):3003–3004. PubMedCrossRef
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMedCrossRef
van Bronswijk SC, DeRubeis RJ, Lemmens LHJM, et al. Precision medicine for long-term depression outcomes using the Personalized Advantage Index approach: cognitive therapy or interpersonal psychotherapy? Psychol Med. 2021;51(2):279–289. PubMedCrossRef
Cipriani A, Geddes J. Predicting treatment outcome in depression: so far, so good. Lancet Psychiatry. 2016;3(3):192–194. PubMedCrossRef
Deshauer D, Moher D, Fergusson D, et al. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ. 2008;178(10):1293–1301. PubMedCrossRef
Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260. PubMedCrossRef
Driessen E, Hollon SD, Bockting CLH, et al. Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? a systematic review and meta-analysis of US National Institutes of Health-funded trials. PLoS One. 2015;10(9):e0137864. PubMedCrossRef
Gabriel FC, de Melo DO, Fráguas R, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS One. 2020;15(4):e0231700. doi:10.1371/journal.pone.0231700
Zafra-Tanaka JH, Goicochea-Lugo S, Villarreal-Zegarra D, et al. Characteristics and quality of clinical practice guidelines for depression in adults: a scoping review. BMC Psychiatry. 2019;19(1):76. PubMedCrossRef
Malmivaara A. Generalizability of findings from randomized controlled trials is limited in the leading general medical journals. J Clin Epidemiol. 2019;107:36–41. PubMedCrossRef
Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(8):1276–1280. PubMedCrossRef
van der Lem R, de Wever WW, van der Wee NJ, et al. The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice. BMC Psychiatry. 2012;12(1):192. PubMedCrossRef
von Wolff A, Jansen M, Hölzel LP, et al. Generalizability of findings from efficacy trials for chronic depression: an analysis of eligibility criteria. Psychiatr Serv. 2014;65(7):897–904. PubMedCrossRef
Duhoux A, Fournier L, Menear M. Quality indicators for depression treatment in primary care: a systematic literature review. Curr Psychiatry Rev. 2011;7(2):104–137. CrossRef
Setkowski K, Boogert K, Hoogendoorn AW, et al. Guidelines improve patient outcomes in specialised mental health care: a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144(3):246–258. PubMedCrossRef
Fortney J, Rost K, Zhang M, et al. The relationship between quality and outcomes in routine depression care. Psychiatr Serv. 2001;52(1):56–62. PubMedCrossRef
Sewitch MJ, Blais R, Rahme E, et al. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use. Can J Psychiatry. 2007;52(3):191–200. PubMedCrossRef
Simon GE, Von Korff M, Rutter CM, et al. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58(4):395–401. PubMedCrossRef
Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. impact on depression in primary care. JAMA. 1995;273(13):1026–1031. PubMedCrossRef
Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMedCrossRef
Saunders EFH, Brady M, Mukherjee D, et al. Gender differences in transdiagnostic domains and function of adults measured by DSM-5 assessment scales at the first clinical visit: a cohort study. BMC Psychiatry. 2023;23(1):709. PubMedCrossRef
Gomaa H, Baweja R, Mukherjee D, et al. Transdiagnostic and functional predictors of depression severity and trajectory in the Penn State Psychiatry Clinical Assessment and Rating Evaluation System (PCARES) registry. J Affect Disord. 2022;298(Pt A):86–94. PubMedCrossRef
Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(suppl E1):e04. PubMedCrossRef
Wang HR, Bahk WM, Seo JS, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci. 2017;15(3):199–209. PubMedCrossRef
American Psychiatric Association. Practice Guideline For the Treatment of Patients With Major Depressive Disorder. Published November 2010. Accessed August 24, 2023. https://psychiatryonline.org/guidelines
Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152. PubMedCrossRef
Malmivaara A. Methodological considerations of the GRADE method. Ann Med. 2015;47(1):1–5. PubMedCrossRef
Yang L, Su Y, Dong S, et al. Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China. Front Pharmacol. 2022;13:954973. PubMedCrossRef
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMedCrossRef
Kroenke K, Spitzer RL, Williams JBW, et al. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–359. PubMedCrossRef
Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMedCrossRef
Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32(12):2479–2489. PubMedCrossRef
Herzog DP, Wagner S, Ruckes C, et al. Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):711–721. PubMedCrossRef
Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMedCrossRef